Cyclacel pharmaceuticals reports third quarter financial results and provides business update

- cyclacel expects to release updated phase 1/2 clinical and biomarker data with oral fadraciclib and provide safety, efficacy and putative mechanism update for oral plogosertib -
CYCC Ratings Summary
CYCC Quant Ranking